Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apotea AB (publ)CHIX:APOTES 18 Receivables Turnover is 5.43 as of Jun. 2026. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 659 Healthcare Providers & Services companies, Apotea AB (publ) ranks better than 84.37% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Apotea AB (publ)'s Revenue for the
three
months ended in Jun. 2026 was kr2,026 Mil. Apotea AB (publ)'s average Accounts Receivable for the
three
months ended in Jun. 2026 was kr373 Mil.
Hence, Apotea AB (publ)'s Receivables Turnover for the
three
months ended in Jun. 2026 was 5.43.
Apotea AB (publ) (CHIX:APOTEs) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Apotea AB (publ) Receivables Turnover Related Terms
Apotea AB (publ) Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Apotea AB (publ)'s Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) Receivables Turnover Competitor Comparison
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) (CHIX:APOTES) has a Receivables Turnover of 5.43 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Apotea AB (publ) and its competitors. According to the industry distribution chart, Apotea AB (publ) ranks #103 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 15.6%.
Is Apotea AB (publ)'s Receivables Turnover too high?
Apotea AB (publ)'s current Receivables Turnover is 5.43. The Healthcare Providers & Services industry median Receivables Turnover is 7.75. Apotea AB (publ)'s value of 5.43 is 29.9% below this industry median. Based on the distribution chart, Apotea AB (publ) ranks #103 out of 659 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s Receivables Turnover compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #103 out of 659 companies for Receivables Turnover. This places Apotea AB (publ) in the top 16% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 7.75. Apotea AB (publ)'s value of 5.43 is 29.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.75, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apotea AB (publ)'s current Receivables Turnover of 5.43 is 29.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current Receivables Turnover is 5.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current Receivables Turnover of 5.43. The current Receivables Turnover is 5.43 and 29.9% below the Healthcare Providers & Services industry median of 7.75. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current Receivables Turnover is 5.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
